Abraxis (ABII)

[surf1944]

6:01PM Abraxis BioScience: Second trial with ABRAXANE to demonstrate increased survival in patients with advanced pancreatic cancer;at the 46th Annual Meeting of the American Society of Clinical Oncology (ABII) : Co previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound (nab) driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer.. A phase 2 clinical study evaluating nab-paclitaxel (100 mg/m2) in advanced pancreatic cancer patients who have progressed on gemcitabine-based therapy (Abstract #4120), treatment resulted in 58% of patients achieving six-month overall survival (OS), with a median survival of 7.3 months and a median progression-free survival (PFS) of 1.6